The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Effects of a Flaxseed-Derived Lignan Supplement in Type 2 Diabetic Patients: A Randomized, Double-Blind, Cross-Over Trial
Open accessAbstract
BACKGROUND: Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. METHODOLOGY/PRINCIPAL FINDINGS: This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA(1c) (-0.10+/-0.65 % vs. 0.09+/-0.52 %, P = 0.001) compared to placebo; however, no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2+/-18.1 vs. 1.2+/-2.4 microg/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations. CONCLUSIONS/SIGNIFICANCE: Daily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT00363233.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids
Anderson, J. W., Johnstone, B. M., & Cook-Newell, M. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330502 · Cited by 2,048
Management of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786
Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed
Prasad, K. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.11.012 · Cited by 232 · cited 1×
“Recently, two studies reported that secoisolariciresinol diglucoside (SDG), the major plant lignan in flaxseed [11], significantly reduced total cholesterol and LDL cholesterol (LDL-C) concentrations in rabbits [12,13].”
Background
Cited by
Peterson, J., Dwyer, J., Adlercreutz, H., Scalbert, A., Jacques, P., & McCullough, M. L. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00319.x · Cited by 376
Franz, M. J., MacLeod, J., Evert, A., Brown, C., Gradwell, E., Handu, D., Reppert, A., & Robinson, M. (2017) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2017.03.022 · Cited by 349
“Sixty studiesmet inclusion criteria and were reviewed.(13-73) Twenty-two were related to effectiveness of MNT provided by RDNs(13-35) and 38 studieswere related to diabetes nutrition interventions.”
BackgroundHealth Effects with Consumption of the Flax Lignan Secoisolariciresinol Diglucoside
Adolphe, J. L., Whiting, S. J., Juurlink, B. H. J., Thorpe, L. U., & Alcorn, J. (2010) · British Journal of Nutrition · doi:10.1017/s0007114509992753 · Cited by 314
“…compared with placebo (9) Men with benign prostatic hyperplasia receiving 600mg SDG/d had an improved quality of life score compared with placebo (26) Pan et al. (2007) (53) ; Pan et al. (2009) (54) 360mg/d from lignan capsules Supplementation reduced HbA1C compared with placebo in participants…”
InfluentialPharmaceutical Drugs and Natural Therapeutic Products for the Treatment of Type 2 Diabetes Mellitus
Blahova, J., Martiniakova, M., Babikova, M., Kovacova, V., Mondockova, V., & Omelka, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080806 · Cited by 302
Guasch-Ferré, M., Merino, J., Sun, Q., Fitó, M., & Salas-Salvadó, J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/6723931 · Cited by 297
“In the first intervention study, including 70 adults with T2D, those participants consuming olive leaf extract (500mg) exhibited significantly lower HbA1c and fasting plasma insulin levels; however, postprandial plasma insulin levels did not differ significantly by treatment group [50].”
BackgroundInfluential
Metadata
- Authors
- Pan, A., Sun, J., Chen, Y., Ye, X., Li, H., Yu, Z., Wang, Y., Gu, W., Zhang, X., Chen, X., Demark-Wahnefried, W., Liu, Y., & Lin, X.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-11-07
- Volume
- 2
- Issue
- 11
- Pages
- e1148
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2046453040
- Cited by
- 194
- References
- 4
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.